Comparison of Renal Outcomes of Belimumab versus Immunosuppressants (IS) in Participants With Systemic Lupus Erythematosus (SLE)
Trial overview
Time to Composite Outcome (TTCO) of Renal Flare (Moderate or Severe) or Progression to Lupus Nephritis (LN)
Timeframe: Up to approximately 9.25 years from index date
Time to Progression to LN (TTLN)
Timeframe: Up to approximately 9.25 years from index date
Time to First Moderate or Severe Renal Flare
Timeframe: Up to approximately 9.25 years from index date
TTCO and TTLN Among Participants With and Without Baseline Organ Damage
Timeframe: Up to approximately 9.25 years from index date
TTCO and TTLN Among Participants With Mild SLE Disease and Participants With Moderate or Severe SLE Disease During the 6 Months Before Index Date
Timeframe: Up to approximately 9.25 years from index date
TTCO and TTLN Among Participants With Government-sponsored Insurance and Participants With Commercial Insurance at Index Date
Timeframe: Up to approximately 9.25 years from index date
TTCO and TTLN Among Participants With at least 12 Months of Continuous Enrollment After Index Date
Timeframe: Up to approximately 9.25 years from index date
- Initiation of treatments of interest on or after 01 January 2017 (date of initiation defined as the index date):
- o For belimumab cohort: greater than or equal to (>=) 1 claim for treatment with belimumab OR
- >= 1 claim for diagnosis of drug-induced lupus, any time before the index date
- >= 1 indicator of LN, any time before the index date, defined as:
- Azathioprine
- Methotrexate
- Diagnosis of SLE any time from the start of data availability date through the index date, based on: o >= 1 inpatient (IP) claim, OR o >= 2 outpatient (OP)/emergency department (ED) medical claims separated by >= 60 days
- >= 12 months of continuous enrollment before index date (i.e., baseline period)
- Use of prior treatment during baseline period : o >= 1 claim for hydroxychloroquine or chloroquine OR o >= 1 claim for an oral glucocorticoid (OGC) at a prednisone-equivalent dose less than (<) 20 milligrams per day (mg/day)
- The OGC dose will be calculated as the (quantity of tablets/capsules * prednisone-equivalent dose of each tablet/capsule) divided by the days of supply on the claim (e.g., the OGC dose for a claim with 60 tablets of 5 milligrams [mg] prednisone-equivalent dose with days of supply of 30 days will be 10 mg/day). As OGC may have different dosage forms, doses of different OGC will be converted to equivalent prednisone strengths, based on the potencies and duration of action of the OGC. The conversions for the equivalent dose of each OGC to 7.5 mg of prednisone were extracted from literature and medical references.
Initiation of treatments of interest on or after 01 January 2017 (date of initiation defined as the index date): o For belimumab cohort: greater than or equal to (>=) 1 claim for treatment with belimumab OR o For SOC IS cohort: >= 1 claim for at least one of the following SOC IS treatments for SLE:
Mycophenolate mofetil/mycophenolic acid (MMF)
- >= 1 indicator of LN, any time before the index date, defined as: o >= 1 claim with LN diagnosis codes OR o >= 2 claims with renal diagnosis codes on distinct dates, OR o >= 2 claims for any nephrologist encounters on distinct dates (regardless of presence of a renal diagnosis code in those claims), OR o >= 1 claim for renal biopsy test (regardless of presence of a renal diagnosis code in those claims)
- >= 1 claim for belimumab or anifrolumab (i.e., biologics indicated for SLE treatment), or rituximab (a biologic commonly used off-label for SLE treatment) during the baseline period
- >= 1 claim for an SOC IS (i.e., azathioprine, methotrexate, or MMF) during the baseline period
- >= 1 claim for diagnosis of polycystic kidney disease or kidney cancer any time before the index date
- >= 1 claim for dialysis or kidney transplant any time before the index date
- >= 1 measurement of estimated glomerular filtration rate (eGFR) < 15 milliliters per minute per 1.73 square meters (mL/min/1.73 m^2) any time before the index date
- >= 1 claim for diagnosis of end-stage renal disease (ESRD) any time before the index date
- >= 1 claim for voclosporin during the baseline period
- >= 1 renal flare during the baseline period
>= 1 claim for diagnosis of drug-induced lupus, any time before the index date
Trial location(s)
No location data available.
Study documents
No study documents available.
Results overview
No study documents available
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.